Beam Therapeutics (MEX:BEAM) Growth Rank: 4 (As of Aug. 05, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BEAM Beam Therapeutics Inc MEX:BEAM
67 GF Score
Price MXN436.81
GF Value MXN455.36
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics Growth Rank?

Beam Therapeutics MEX:BEAM 67 Growth Rank is 4 as of Aug. 05, 2026, which is at its 10-year median of 4.00. GuruFocus rates MEX:BEAM with a GF Score™ of 67/100 and a GF Value™ of MXN455.36 (Fairly Valued). The stock has 4 warning signs investors should review.

Beam Therapeutics has the Growth Rank of 4.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Beam Therapeutics Growth Rank Related Terms

MEX:BEAM vs KOD, TARS, VERA: Growth Rank Comparison

For the Biotechnology subindustry, Beam Therapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beam Therapeutics Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Beam Therapeutics's Growth Rank falls into.


MEX:BEAM
67GF Score
Beam Therapeutics Inc MEX:BEAM
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 4 mean?
Beam Therapeutics (MEX:BEAM) has a Growth Rank of 4 as of Aug. 05, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Beam Therapeutics and its competitors. This is near median its historical median of 4.00. Over the past decade, Beam Therapeutics' Growth Rank has ranged from 3.00 to 4.00.
Is Beam Therapeutics' Growth Rank too high?
Beam Therapeutics' current Growth Rank of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 4.00. Overall, Beam Therapeutics has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Growth Rank compare to KOD and TARS?
Beam Therapeutics' Growth Rank of 4 can be compared against companies in the Biotechnology industry. Historically, Beam Therapeutics' own Growth Rank has ranged from 3.00 to 4.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Growth Rank is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Fairly Valued. The stock's GF Value™ is MXN455.36, compared to a current price of MXN436.81 — trading 4.1% below its estimated fair value. The current Growth Rank is 4, which is near median its 10-year median of 4.00. Beam Therapeutics' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Growth Rank is 4 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued. The current stock price of MXN436.81 is trading 4.1% below its estimated GF Value™ of MXN455.36. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for MEX:BEAM:

  • Growth Rank: 4 (near median its 10-year median of 4.00)
  • GF Value™: MXN455.36 vs. price of MXN436.81 (4.1% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
67GF Score

Get the complete analysis for MEX:BEAM

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN436.81
Price
MXN455.36
GF Value